About ExoSurge®
We invested over twenty-million dollars developing this breakthrough technology that measurably and permanently removes the plaque and fibrosis associated with Peyronie's Disease.
Our patented device and drug therapies combine a regulated flow of inter-fibrinous pulsated gases with select intralesional drug injections that has been clinically-proven to permanently remove the plaques that cause Peyronie's disease. Our years of research and development understanding the epidemiology of Peyronie's plays a key role in our technology's success.
Our core team is composed of life science veterans, with more than 150 years of life science experience, multiple device clearances, and national company launches.
Our patented device and drug therapies combine a regulated flow of inter-fibrinous pulsated gases with select intralesional drug injections that has been clinically-proven to permanently remove the plaques that cause Peyronie's disease. Our years of research and development understanding the epidemiology of Peyronie's plays a key role in our technology's success.
Our core team is composed of life science veterans, with more than 150 years of life science experience, multiple device clearances, and national company launches.
Clinically Focused
To date, we remained focused as a Medtech and Biotech R&D enterprise comnined with a retail clinical treatment platform. Now we’ve begun taking steps toward our next level of evolution.
We’re committed to holding our technology and its applications to the highest scientific standards, including upcoming clinical trials for current and future applications. We also believe in education and transparency. We plan to broaden our clinical trials to include other indications.
Explore our technology and roadmap
To date, we remained focused as a Medtech and Biotech R&D enterprise comnined with a retail clinical treatment platform. Now we’ve begun taking steps toward our next level of evolution.
We’re committed to holding our technology and its applications to the highest scientific standards, including upcoming clinical trials for current and future applications. We also believe in education and transparency. We plan to broaden our clinical trials to include other indications.
Explore our technology and roadmap
Research and Development
Our company mission is anchored from innovation. We forever continue to innovate along three core disciplines
Incremental Innovation: Improvements to our base ExoSurge® technology as it relates to healing Peyronie’s disease. This includes continued refinement with approaches to case diagnosis so we can more effectively educate each patient, and improvements to protocols, devices and drugs that can cause a fast and better healing paradigm.
Breakthrough Opportunities: Exploration of alternative applications for our breakthrough ExoSurge technology and device.
Transformational R&D: We believe our innovation of ExoSurge® as a conservative, permanent resolution for Peyronie’s is a transformational innovation. We believe there might be an additional transformational innovation opportunity within the underlying essence of our invention and we are exploring new ideas within that framework.
Our company mission is anchored from innovation. We forever continue to innovate along three core disciplines
Incremental Innovation: Improvements to our base ExoSurge® technology as it relates to healing Peyronie’s disease. This includes continued refinement with approaches to case diagnosis so we can more effectively educate each patient, and improvements to protocols, devices and drugs that can cause a fast and better healing paradigm.
Breakthrough Opportunities: Exploration of alternative applications for our breakthrough ExoSurge technology and device.
Transformational R&D: We believe our innovation of ExoSurge® as a conservative, permanent resolution for Peyronie’s is a transformational innovation. We believe there might be an additional transformational innovation opportunity within the underlying essence of our invention and we are exploring new ideas within that framework.
We weren't looking to create another Peyronie's treatment
After a fellow urologist from California visited our clinic and saw our results treating Peyronie's at the time, our development team went through a transformative experience in 2015.
"We needed to publish ASAP," this doctor exclaimed. We knew our technology was already superior to established therapies at the time, but we hadn't yet isolated all of the variables within the disease's epidemiology, so we still encountered cases we couldn't improve.
It was tempting to jump into the forefront of Peyronie's care because we also had a firm offering us a monetization path.
"Did we all sign-on for this maddening project because we wanted to provide another treatment for Peyronie's, or did we commit to developing a cure for Peyronie's?" asked one of our junior associates who is no longer with our team.
She was correct.
None of us agreed to work this hard just to develop another treatment. We were determined to find a cure.
Since then, we haven't looked back.
Our Origins
Founder / Visionary
Steven L. Morganstern, MD is an internationally acclaimed Urologist and surgeon, with an innovative specialization in men’s sexual health. He was on the front lines of erectile dysfunction (ED) therapeutics, both with pioneering bioidentical testosterone pellet therapy and assisting on the front lines of the launch of inflatable prosthetic implants alongside of inventor Brantley Scott, MD. He served as a leading media spokesperson and expert regarding erectile dysfunction well before others were talking about it.
He was chosen as the only private clinician to be included in the original trials for Viagra. Dr. Morganstern’s medical journey spans over four decades and includes key innovations in penis implants, prostate cancer, male hormone replacement therapy, benign prostrate problems, and HGH treatments.
Dr. Morganstern's twenty-year odyssey to develop a cure for Peyronie's Disease despite ridicule from established urology is represented by ExoSurge technology. His perseverance and vision in discovering the secrets to curing Peyronie's disease continue to inspire us all.
Co-Founder / Chief Medical Officer
Following a successful 20-year career as a professor of urology at Emory University and as chief of urology at Emory's "Grady Memorial Hospital", one of the nations most famed trauma center, Dr. Carney began consulting with EXO in the development of our Peyronie's technology beginning in 2017.
Dr. Carney left Emory to join EXO full time during 2022 and his skills and leadership had an immediate impact
Dr. Carney's renown in urologic trauma has been vital to the evolution of ExoSurge technology and he now leads our group of Peyronie's clinicians.
Rayvon Reynolds
Rayvon Reynolds unearthed the hidden value in Dr. Morganstern's urologic clinical platform in 2014 and has been the driving force behind the development of ExoSurge's technology for the past seven years.
Previously, Rayvon was co-founder and inventor of a consumer packaged goods product venture in partnership with Woolite®. Rayvon leveraged this direct experience with utility patents (Rayvon personally has eleven patents) to help guide protections for ExoSurge's IP assets.
Previously, Rayvon as a recognized innovator creating modernization for ultra-high single-unit retail sales and served as president of Moby Dick Seafood Restaurants national company. Moby Dick was the nation’s fourth largest fast-seafood chain at that time.
ExoSurge Clinical Director
Mrs. Bates joined Morganstern Urology as a Nurse Practitioner in 2018 and became a skilled administrator of our Peyronie's treatment paradigm and helped incubate standardized patient case evaluation and management systems for ExoSurge patients.
When she's not helping build race cars with her sons and husband, she stays focused on improvements to diagnostics and vetting of initial patient evaluations in order to speed outcomes with Peyronie's clinical care.
She is directing efforts to create a supporting treatment algorithm for future clinicians that leverages and seeks to automate our insights with Peyronie's epidemiology with our long history treating varied cases and fibrous tissue plaques.
Director, Medical Sciences
Scott Baker dedicated his entire career to healthcare. Over the past seven years as we tested, refined and developed new technologies – Scott remained on the forefront of each patient’s treatment protocol and the helping revise optimal applications.
He leads the charge managing most of our operational technology and helping validate the sciences behind them. He also manages leverages this knowledge with his innate attention to detail into success managing logistics for our expansion directives.
Director, Peyronie's Surgical Research
Dan Toubiana, PA is not only one f our most requested ExoSurge treatment providers, he's also manager for many of our reconstructive surgical procedures, directly assisting Dr. Carney.
joined, left, and later re-joined the EXO team
Along with providing care for Peyronie's clinical patients, Dan is focused on a couple of new directives for the future including how ExoSurge technology can be used to improve outcomes for traditional Peyronie's surgery patients.
Science Advisory Board
John Mulcahy, MD is an Emeritus professor of urology at Indiana University and clinical professor of urology at both the University of Arizona and the University of Alabama. He’s one of only a handful of elite urologists from around the globe to be listed in the Canadian Journal of Urology’s “Legends of Urology”. His main areas of interest have been urinary incontinence and erectile dysfunction and he pioneered many treatments and surgical procedures in these areas resulting in recognition including the Cristol Award from the Mayo Urologic Alumni Association and the Brantley Scott Award from the Bladder Health Council of the American Foundation for Urologic Diseases for significant contributions to Urology. He wrote over 100 publications and edited 4 urology textbooks. He continues to teach urology residents prosthetic implantation and repair techniques and frequently gives grand rounds presentations on topics related to erectile dysfunction and male urinary incontinence. Dr. Mulcahy is presently consulting with ExoSurge regarding the standards for its planned prospective clinical trials. His credentials are highly respected, and his insights are augmented by the fact we first treated him as a patient: he’s seen first-hand what this technology can do for urology and men’s healthcare.
Our Growing Team
In order to deliver our complex, breakthrough technology to patients and the healthcare community, we are recruiting some of the country’s leading medical professionals within Peyronie’s Disease care to help refine and improve our core technology.
We have already identified and recruited select candidates for key roles and look forward to sharing details about new team members in the future.
Stay Up To Date
If you are a Peyronie's patient who has interest in participating in one of our upcoming clinical trials around the United States, please click here
If you are a urologic clinician who has a potential interest with being involved in our upcoming prospective clinical trials, please click here
If you would like to stay abreast of our progress during clinical trials and in the future, please click here:
Sign up to follow our story and to watch us grow!